Breast Cancer | Topics

Greater Ki67 Suppression Achieved With Giredestrant Compared With Anastrozole in ER+/HER2– Early Breast Cancer
September 21, 2021

Consistent Ki67 suppression with giredestrant was noted in a phase 2 trial versus anatrozole.

Patients With Postmenopausal HR+/HER2– Advanced Breast Cancer Experience Notable OS Benefit With Ribociclib/Letrozole Combo
September 19, 2021

Data from the phase 3 MONALEESA-2 trial demonstrate significant benefit of frontline ribociclib (Kisqali) added to letrozole for hormone receptor–positive, HER2-negative advanced breast cancer

[vic]-Trastuzumab Duocarmazine Improved Survival For HER2-Positive Metastatic Breast Cancer
September 19, 2021

Treatment [vic]-trastuzumab duocarmazine improved progression-free survival for patients with pretreated, metastatic HER2-positive breast cancer when compared with physician’s choice chemotherapy.